文献速递青光眼

LiGHT 试验视野结局:首选药物治疗与首选 SLT 的对比

Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).
PubMed 文献 · Ophthalmology · 2020-04-03

该研究为 LiGHT 随机对照试验的二次分析,比较首选药物治疗与首选选择性激光小梁成形术(SLT)的高眼压及青光眼患者的视野结局。结果显示药物治疗组中发生中度或快速视野进展的眼睛比例略高于 SLT 组。

要点

  • 药物治疗组有 26.2% 的眼睛出现中度或快速 TD 进展,SLT 组为 16.9%(RR 1.55,95%CI 1.23-1.93,P<0.001)。
  • 点wise TD 进展比例药物治疗组 26.1%,SLT 组 19.0%(RR 1.37,95%CI 1.33-1.42,P<0.001)。
  • 点wise PD 进展比例药物治疗组 11.5%,SLT 组 8.3%(RR 1.39,95%CI 1.32-1.46,P<0.001)。

核心结论

  • 首选药物治疗的高眼压和青光眼患者中,发生快速视野进展的比例略高于首选 SLT 治疗者。

研究设计与样本

  • LiGHT 多中心随机对照试验的二次分析,纳入首选药物治疗组 344 例(588 眼)和首选 SLT 组 344 例(590 眼)。
  • 视野检查采用标准自动视野计,中位系列长度为 9 次视野检查、持续 48 个月,使用分层线性模型估计点wise进展率并平均为全局进展估计。

主要发现

  • 药物治疗组有 26.2% 的眼睛发生中度或快速 TD 进展,SLT 组为 16.9%(RR 1.55,95%CI 1.23-1.93,P<0.001)。
  • 点wise TD 进展率被归类为中度或快速的比例:药物治疗组 26.1%,SLT 组 19.0%(RR 1.37,95%CI 1.33-1.42,P<0.001)。
  • 点wise PD 进展率被归类为中度或快速的比例:药物治疗组 11.5%,SLT 组 8.3%(RR 1.39,95%CI 1.32-1.46,P<0.001)。
  • 发生中度或快速 PD 进展的眼睛比例在两组间无统计学差异(药物治疗组 9.9% vs SLT 组 7.1%;RR 1.39;95%CI 0.95-2.03;P=0.0928)。

关键数值与推荐

  • 快速进展定义为视野进展率 < -1 dB/年,中度进展定义为 < -0.5 dB/年。

临床怎么用

  • 在决定高眼压或青光眼患者的初始治疗时,可将 SLT 作为与药物治疗相当的选项,以可能降低快速视野进展的风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare visual field outcomes of ocular hypertensive and glaucoma patients treated first with medical therapy with those treated first with selective laser trabeculoplasty (SLT). DESIGN: Secondary analysis of patients from the Laser in Glaucoma and Ocular Hypertension study, a multicenter randomized controlled trial. PARTICIPANTS: Three hundred forty-four patients (588 eyes) treated first with medical therapy and 344 patients (590 eyes) treated first with SLT. METHODS: Visual fields (VFs) were measured using standard automated perimetry and arranged in series (median length and duration, 9 VFs over 48 months). Hierarchical linear models were used to estimate pointwise VF progression rates, which were then averaged to produce a global progression estimate for each eye. Proportions of points and patients in each treatment group with fast (<-1 dB/year) or moderate (<-0.5 dB/year) progression were compared using log-binomial regression. MAIN OUTCOME MEASURES: Pointwise and global progression rates of total deviation (TD) and pattern deviation (PD). RESULTS: A greater proportion of eyes underwent moderate or fast TD progression in the medical therapy group compared with the SLT group (26.2% vs. 16.9%; risk ratio [RR], 1.55; 95% confidence interval [CI], 1.23-1.93; P < 0.001). A similar pattern was observed for pointwise rates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001). A greater proportion of pointwise PD rates were categorized as moderate or fast in the medical therapy group (medical therapy, 11.5% vs. SLT, 8.3%; RR, 1.39; 95% CI, 1.32-1.46; P < 0.001). No statistical difference was found in the proportion of eyes that underwent moderate or fast PD progression (medical therapy, 9.9% vs. SLT, 7.1%; RR, 1.39; 95% CI, 0.95, 2.03; P = 0.0928). CONCLUSIONS: A slightly larger proportion of ocular hypertensive and glaucoma patients treated first with medical therapy underwent rapid VF progression compared with those treated first with SLT.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wright DM, Konstantakopoulou E, Montesano G, et al. Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT). Ophthalmology. 2020. PMID: 32402553. doi:10.1016/j.ophtha.2020.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。